Biosimilars - the Brexit of the pharmaceutical industry?
In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities of Britain exiting the EU (Brexit).
availability of biosimilars for nearly a decade, uptake in the UK is still
lagging behind other EU markets, leading to the recent formation of the British Biosimilars Association (BBA) - part of the British Generic Manufacturers Association (BGMA).
are undoubtedly a hot topic for providers of branded biologic medicines,
biosimilar suppliers themselves, and the payers, healthcare professionals and
patients involved in biologic treatment. Much like the EU referendum, they
feature regularly in the news - with spectators waiting anxiously, in some
cases eagerly, for a change that could alter the treatment landscape for
several significant therapy areas.
understand the factors influencing the uptake of biosimilars you could apply
the same principles as you would to navigating the complexities of Britain
exiting the EU (Brexit).
1. Control is in the
hands of the people
relationship with the EU will be decided by a referendum, placing the decision
in the hands of the people. In the UK, the decision to prescribe a biosimilar
is still largely down to the healthcare professional (HCP) but, if this were to change, impact on
biologic markets could be dramatic.Despite NICE recommending
biosimilars ahead of branded biologics in several disease areas, this does not
appear to be happening in clinical practice. The next step for governing bodies
to ensure biosimilars are prioritised in the treatment pathway is substitution,
replacing a branded biologic with its corresponding biosimilar at point of
dispensing; a move that would result in a huge uplift in biosimilar use.Arguably,
the reason this hasn’t happened yet is that the financial gain generated by
such a move does not yet outweigh the repercussions of reducing the role of the
HCP in such an important decision. But with increasing pressure on the NHS to
make cost savings and expect greater value from treatments, this could change
in the future.
As a business that works with healthcare and pharma companies, it’s not often that we get the opportunity to design the cover for Time Out London, so we jumped at the chance to partner with Rays of Sunshine to help them get the word out about their #Kisses4Wishes campaign on Valentine’s Day. Liz Inskip talked with the creative team about the campaign and how BLH approaches this kind of work.
Blue Latitude Health
When we talk about customers as experts in healthcare, what we’re really talking about are clinicians. Experts in diagnosis, treatment and clinical care (HCPs) and experts as those who experience the medical condition in their own personal context (patients). Head of Customer Experience Elisa del Galdo talks through how the evolution of the relationship between HCPs and patients is changing the role of the expert in healthcare.
Blue Latitude Health
Simon Young, Director at Blue Latitude Health, discusses how advances in technology are influencing the future of the expert-patient relationship and why healthcare businesses must evaluate how best to support the future role of the expert. Blue Latitude Health
Content Marketing Manager Liz Inskip interviews Neil Maiden of City, University of London, about his work developing mobile technology solutions for residential dementia care, and what the challenges facing innovators in this therapy area are. Blue Latitude Health
The last decade has seen the rapid growth of biologics in the pharma market, making them a key sector to watch. With their growing popularity, it’s important to understand the opportunities and threats they present. Associate Consultant Ditte Funding takes us through how biologics are made, what makes them unique, and what it all means for pharma companies. Blue Latitude Health